Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurel Sweet

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cell|October 19, 2020
Raymond L. Erikson (1936-2020)Benjamin G Neel, Laurel Sweet, Daniel L Simmons, et al.
Bioorganic & Medicinal Chemistry Letters|November 9, 2005
Substituted indanylacetic acids as PPAR-alpha-gamma activatorsDerek B Lowe, Neil Bifulco, William H Bullock, et al.
Bioorganic & Medicinal Chemistry Letters|July 3, 2007
Indanylacetic acids as PPAR-delta activator insulin sensitizersPhilip Wickens, Chengzhi Zhang, Xin Ma, et al.
Journal of Medicinal Chemistry|December 27, 2011
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitusJeffrey A Pfefferkorn, Angel Guzman-Perez, John Litchfield, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cell|October 19, 2020
Raymond L. Erikson (1936-2020)Benjamin G Neel, Laurel Sweet, Daniel L Simmons, et al.
Bioorganic & Medicinal Chemistry Letters|November 9, 2005
Substituted indanylacetic acids as PPAR-alpha-gamma activatorsDerek B Lowe, Neil Bifulco, William H Bullock, et al.
Bioorganic & Medicinal Chemistry Letters|July 3, 2007
Indanylacetic acids as PPAR-delta activator insulin sensitizersPhilip Wickens, Chengzhi Zhang, Xin Ma, et al.
Journal of Medicinal Chemistry|December 27, 2011
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitusJeffrey A Pfefferkorn, Angel Guzman-Perez, John Litchfield, et al.
Pageof 1